Incidence of Significant Mitral Regurgitation in Acute Heart Failure Patients (MRAHF)

Metanoic Health

Status: Completed

Conditions: Mitral Regurgitation; Acute Heart Failure

Treatments: Procedure: Transthoracic Echocardiogram (TTE) Assesment

Study type: Interventional

Funder types: Industry

Identifiers

NCT02728739

MHL-2016-001

Details and patient eligibility

About

The purpose of this study is to determine the prevalence of moderate-to-severe Mitral Regurgitation (MR) in acute Heart Failure (HF) patients requiring hospital admission.

Full description

All patients admitted with symptoms of HF- (shortness of breath (SOB), peripheral oedema, palpitations and irregular heart beats) will be assessed by the Research Team. The level of BNP will be checked using a small device (i-STAT BNP) at the bedside. If results of the test suggest HF they will undergo special procedure called transthoracic echocardiography (TTE). TTE is an ultrasound scan of the heart which will enable the investigators' to grade severity of Mitral Regurgitation (MR) as well as strength of the heart muscle. The investigators will use bi-plane Simpton's method to calculate left ventricular (LV) ejection fraction (EF). Colour Doppler and PISA method will be used to quantify severity of MR or valve leak. Simultaneously there will be recording of heart sounds to find out if auscultation is reliable in identifying leaky valves.

Enrollment: 500 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Acute Heart Failure patients admitted to the Hospital
• Elevated BNP level (>30pg/ml)

Exclusion criteria

• Patients with BNP level (< 30pg/ml)

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

500 participants in 1 patient group

Acute Heart Failure Patients

Experimental group

Description:

Acute Heart Failure patients with elevated levels of BNP ( >30pg/ml) will undergo Transthoracic Echocardiogram (TTE) for grading of MR severity within 7 days.

Treatment:

Procedure: Transthoracic Echocardiogram (TTE) Assesment